BioCentury | Apr 18, 2011
Clinical News

TriN 2755: Interim Phase I data

...In 3 evaluable patients receiving once-weekly TriN 2755, there were no cases of stable disease. TriN...
...and the MTD has not yet been reached. Once-monthly 4,000 and 5,000 mg cohorts of TriN...
...American Association for Cancer Research meeting in Orlando. Trin Therapeutics GmbH , Dusseldorf, Germany Product: TriN...
BioCentury | Nov 16, 2009
Company News

Trin management update

Trin Pharma GmbH , Appenzell, Switzerland Business: Cancer Promoted: Stefan Wohlfeil to CEO from CMO WIR Staff...
BioCentury | Nov 16, 2009
Clinical News

TRIN 2755: Phase I started

...an open-label, dose-escalation, German Phase I trial to evaluate weekly and monthly dosing of intravenous TRIN...
...in an extension study once a MTD has been identified. Trin Pharma GmbH , Appenzell, Switzerland Product: TRIN...
Items per page:
1 - 3 of 3
BioCentury | Apr 18, 2011
Clinical News

TriN 2755: Interim Phase I data

...In 3 evaluable patients receiving once-weekly TriN 2755, there were no cases of stable disease. TriN...
...and the MTD has not yet been reached. Once-monthly 4,000 and 5,000 mg cohorts of TriN...
...American Association for Cancer Research meeting in Orlando. Trin Therapeutics GmbH , Dusseldorf, Germany Product: TriN...
BioCentury | Nov 16, 2009
Company News

Trin management update

Trin Pharma GmbH , Appenzell, Switzerland Business: Cancer Promoted: Stefan Wohlfeil to CEO from CMO WIR Staff...
BioCentury | Nov 16, 2009
Clinical News

TRIN 2755: Phase I started

...an open-label, dose-escalation, German Phase I trial to evaluate weekly and monthly dosing of intravenous TRIN...
...in an extension study once a MTD has been identified. Trin Pharma GmbH , Appenzell, Switzerland Product: TRIN...
Items per page:
1 - 3 of 3